BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Inoue J, Akahane T, Nakayama H, Kimura O, Kobayashi T, Kisara N, Sato T, Morosawa T, Izuma M, Kakazu E, Ninomiya M, Iwata T, Takai S, Nakamura T, Sano A, Niitsuma H, Masamune A; THERME Study Group. Comparison of hepatitis B virus genotypes B and C among chronically hepatitis B virus-infected patients who received nucleos(t)ide analogs: A multicenter retrospective study. Hepatol Res 2019;49:1263-74. [PMID: 31254482 DOI: 10.1111/hepr.13398] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Inoue J, Kobayashi T, Akahane T, Kimura O, Sato K, Ninomiya M, Iwata T, Takai S, Kisara N, Sato T, Nagasaki F, Miura M, Nakamura T, Umetsu T, Sano A, Tsuruoka M, Onuki M, Niitsuma H, Masamune A; THERME Study Group. Non-Achievement of Alanine Aminotransferase Normalization Associated with the Risk of Hepatocellular Carcinoma during Nucleos(t)ide Analogue Therapies: A Multicenter Retrospective Study. JCM 2022;11:2354. [DOI: 10.3390/jcm11092354] [Reference Citation Analysis]
2 Campos-Valdez M, Monroy-Ramírez HC, Armendáriz-Borunda J, Sánchez-Orozco LV. Molecular Mechanisms during Hepatitis B Infection and the Effects of the Virus Variability. Viruses 2021;13:1167. [PMID: 34207116 DOI: 10.3390/v13061167] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fletcher GJ, Eapen CE, Abraham P. Hepatitis B genotyping: The utility for the clinicians. Indian J Gastroenterol 2020;39:315-20. [PMID: 31617082 DOI: 10.1007/s12664-019-00995-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
4 Inoue J, Sato K, Ninomiya M, Masamune A. Envelope Proteins of Hepatitis B Virus: Molecular Biology and Involvement in Carcinogenesis. Viruses 2021;13:1124. [PMID: 34208172 DOI: 10.3390/v13061124] [Reference Citation Analysis]
5 Tsuruoka M, Inoue J, Onishi Y, Ninomiya M, Kakazu E, Iwata T, Sano A, Sato K, Harigae H, Masamune A. Hepatitis B Virus Reactivation with Discontinuation of Nucleoside Analogue in Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation. Case Rep Gastroenterol 2021;15:178-87. [PMID: 33708067 DOI: 10.1159/000512397] [Reference Citation Analysis]
6 Kirino S, Tamaki N, Kurosaki M, Inada K, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Izumi N. Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. J Viral Hepat 2021;28:787-94. [PMID: 33484033 DOI: 10.1111/jvh.13473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Inoue J, Akahane T, Kobayashi T, Obara N, Umetsu T, Kakazu E, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Sato K, Masamune A. Switching to tenofovir disoproxil fumarate in entecavir-treated chronic hepatitis B patients: A pilot randomized controlled study. Biomed Rep 2021;14:20. [PMID: 33335726 DOI: 10.3892/br.2020.1396] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Lapinski TW, Pazgan-simon M, Plesniak R, Sobala-szczygiel B. Loss of HBsAg in Patients with High Levels of HBV-DNA During Treatment with Nucleoside or Nucleotide Analogs. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.106951] [Reference Citation Analysis]
9 Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1039-1052. [PMID: 33007228 DOI: 10.1016/s2468-1253(20)30249-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 16.5] [Reference Citation Analysis]
10 Inoue T, Tanaka Y. Cross-Protection of Hepatitis B Vaccination among Different Genotypes. Vaccines (Basel) 2020;8:E456. [PMID: 32824318 DOI: 10.3390/vaccines8030456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
11 Taniguchi H, Iwasaki Y, Aimi M, Shimazaki G, Moriya A. Clinical features of chronic hepatitis B patients with low hepatitis B surface antigen levels and determinants of hepatitis B surface antigen seroclearance. JGH Open 2020;4:698-706. [PMID: 32782959 DOI: 10.1002/jgh3.12321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ito K. Difference between genotypes B and C in the decline and disappearance of hepatitis B surface antigen: Toward an era of direct-acting antiviral agents for hepatitis B virus. Hepatol Res 2019;49:1253-5. [PMID: 31820538 DOI: 10.1111/hepr.13456] [Reference Citation Analysis]
13 Tamaki N, Kurosaki M, Kirino S, Yamashita K, Osawa L, Sekiguchi S, Hayakawa Y, Wang W, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir. JGH Open 2020;4:429-32. [PMID: 32514449 DOI: 10.1002/jgh3.12273] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]